Meridian Bioscience (Nasdaq: VIVO) reported Q4 EPS of $0.19, in-line with the analyst estimate of $0.19. Revenue for the quarter came in at $48 million versus the consensus estimate of $46.2 million.

Meridian Bioscience reaffirmed FY2015 guidance.

For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.